Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.

doi:10.18632/oncotarget.28565

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.

Oncotarget - 14 Mar 2024

Northcott Josette, Bartha Gabor, Harris Jason, Li Conan, Navarro Fabio C P, Pyke Rachel Marty, Hong Manqing, Zhang Qi, Ma Shuyuan, Chen Tina X, Lai Janet, Udar Nitin, Saldivar Juan-Sebastian, Ayash Erin, Anderson Joshua, Li Jiang, Cui Tiange, Le Tu, Chow Ruthie, Velasco Randy Jerel, Mallo Chris, Santiago Rose, Bruce Robert C, Goodman Laurie J, Chen Yi, Norton Dan, Chen Richard O, Lyle John M

Abstract excerpt

We describe the analytical validation of NeXT Personal®, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay for detecting residual disease, monitoring therapy response, and detecting recurrence in patients diagnosed with solid tumor cancers. NeXT Personal uses whole genome sequencing of tumor and matched normal samples combined with advanced analytics to accurately identify up to ~1,800...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Assay

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Cancer Genomics and Diagnostics

Share to Circulating Tumor DNA

Share to DNA, Neoplasm

Share to Mutation

Share to Neoplasms

Share to Single-cell and spatial transcriptomics

Source

Open in PubMed Open full text

Identifiers

PMID: 38484152
DOI: 10.18632/oncotarget.28565
PMCID: PMC10939476

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.PMID 38484152Read ↗

Analytical Validation of NeXT Personal <sup>®</sup> , an Ultra-sensitive Personalized Circulating Tumor DNA AssaySemantic proximity Read ↗

Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.Semantic proximity Read ↗

Analytical validation and clinical utilization of K-4CARE<sup>TM</sup>: a comprehensive genomic profiling assay with personalized MRD detectionSemantic proximity Read ↗

Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNASemantic proximity Read ↗

Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.Semantic proximity Read ↗

Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNASemantic proximity Read ↗

Analytical and Clinical Validation of an Amplicon-based Next Generation Sequencing Assay for Ultrasensitive Detection of Circulating Tumor DNASemantic proximity Read ↗

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNASemantic proximity Read ↗

Comparison of Target Enrichment Platforms for Circulating Tumor DNA Detection.Semantic proximity Read ↗

Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNASemantic proximity Read ↗

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverageSemantic proximity Read ↗

Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.